Recurrent Stroke Prevention: Diuretic and Angiotensin-Converting Enzyme Inhibitors (ACEIs)—The PROGRESS Trial

Abstract

The rationale and design of the Perindopril Protection Against Secondary Stroke Study (PROGRESS) was published in 1996 (J Hypertens Suppl. 1996;14(6):S47–51), while recruitment had already commenced in 1995. The study design involved a randomized, double-blind, placebo-controlled trial approach in which the blood pressure-lowering component was the angiotensin-converting enzyme inhibiting agent perindopril with and without the addition of the thiazide-like diuretic indapamide. The primary outcome measure was recurrent stroke of all types (fatal, nonfatal, ischaemic and hemorrhagic). The total sample size was over 7000 patients from almost 200 centres in ten countries worldwide with a follow-..